AVROBIO Inc
NASDAQ:TECX

Watchlist Manager
AVROBIO Inc Logo
AVROBIO Inc
NASDAQ:TECX
Watchlist
Price: 21.09 USD -5.76%
Market Cap: 393.5m USD

During the last 3 months AVROBIO Inc insiders bought 7.4m USD , and sold 8.6m USD worth of shares. The stock price has dropped by 14% over this period (open performance analysis).

The last transaction was made on Apr 11, 2025 by Springer Timothy A , who bought 154.6k USD worth of TECX shares.

Last Transactions:
Springer Timothy A
$+154.6k
Mcguire Terrance
Chairman of the Board
$-8.6m
Lochner Daniel
Chief Financial Officer
$+250k
Springer Timothy A
Chief Scientific Officer
$+7m
Springer Timothy A
Chief Scientific Officer
$+10.1m
View All Transactions

During the last 3 months AVROBIO Inc insiders bought 7.4m USD , and sold 8.6m USD worth of shares. The stock price has dropped by 14% over this period (open performance analysis).

The last transaction was made on Apr 11, 2025 by Springer Timothy A , who bought 154.6k USD worth of TECX shares.

Sold
0-3
months
8.6m USD
1
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
2
7.4m USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
1
10.1m USD
9-12
months
No Insider Transactions
0
0 USD

AVROBIO Inc
Insider Trading Chart

AVROBIO Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

AVROBIO Inc
Last Insider Transactions

Global
Insiders Monitor

AVROBIO Inc
Glance View

Market Cap
393.5m USD
Industry
Biotechnology

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The firm is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of five lentiviral-based gene therapy programs, which include AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3, and AVR-RD-03 for the treatment of Pompe disease.

TECX Intrinsic Value
7.55 USD
Overvaluation 64%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top